We work with partners who can help advance our programmes — through co-development, licensing, or joint research on our platforms. Discussions can begin under confidentiality at any stage of development.
| Co-development | Joint advancement of a lead asset | Shared development work spanning formulation, non-clinical package and clinical development. |
| Licensing | Regional or global rights | Licensing of a programme or a platform technology for defined territories or indications. |
| Research collaboration | Platform-level work | Joint work on half-life extension, multi-target engineering or fusion-protein design. |
Out of intellectual-property and commercial-confidentiality considerations, the target, chemical class and structural detail of our investigational compounds are not published on this website; they are made available to prospective partners under a confidentiality agreement.——Global head office: Shanghai
| Fin2678 | Long-acting peptide · weekly · PCC / preclinical |
| Fin0311 | First-in-class peptide · weekly · PCC / preclinical |
| Fin529 | Multi-target peptide · monthly · PCC / preclinical |
| Fin608 | Fusion protein · long-acting · PCC / preclinical |
| Fin611 | Dual-action fusion protein · long-acting · PCC / preclinical |